EVFM · Evofem Biosciences Inc

-

Please sign in to comment on EVFM

1 Comment

Admin

4 years ago

Evofem Biosciences, Inc is currently in a long term downtrend where the price is trading 55.6% below its 200 day moving average.

From a valuation standpoint, the stock is 79.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 281.6.

Evofem Biosciences, Inc's total revenue rose by inf% to $168K since the same quarter in the previous year.

Its net income has dropped by 219.2% to $-41M since the same quarter in the previous year.

Finally, its free cash flow fell by 198.1% to $-40M since the same quarter in the previous year.

Based on the above factors, Evofem Biosciences, Inc gets an overall score of 2/5.

CurrencyCode	USD
ISIN	US30048L2034
Industry	Biotechnology
Sector	Healthcare
Exchange	OTCQB

Beta	-0.87
Market Cap	1M
PE Ratio	None
Target Price	225
Dividend Yield	None

ABOUT

Evofem Biosciences Inc

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a vaginal gel for the prevention of pregnancy; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

EVFM · Evofem Biosciences Inc

-

Evofem Biosciences Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Evofem Biosciences Inc using a moving average strategy